Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llae432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Daniel Hilewitz und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Psoriasis, Inflammatory Bowel Diseases, Drug Eruptions, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Tumour necrosis factor α (TNF-α) inhibitor (TNFi)-induced psoriasiform eruptions are a well-known phenomenon among adults. However, data are limited regarding this reaction in children.
Objectives
To describe in paediatric patients with inflammatory bowel disease (IBD) the clinical characteristics of TNFi-induced psoriasiform eruptions and the outcomes of various therapeutic options.
Methods
We reviewed the medical charts of paediatric patients (aged < 18 years) with IBD who developed TNFi-induced psoriasiform eruptions during 2006–2022.
Results
Among 454 patients with IBD treated with TNFis, 58 (12.8%) were diagnosed with TNFi-induced psoriasiform eruptions, of whom 51 were included in the study. The female to male ratio was 1 : 1.3. The median age at skin eruption was 14.11 [interquartile range (IQR) 12.11–16.05] years. The median elapsed time to eruption appearance was 15.00 months (IQR 7.00–24.00) after initiation of the treatment. All 51 patients were treated with topical steroids and 17 (33%) needed systemic treatment (phototherapy, methotrexate or acitretin). Sixteen of 51 patients (31%) needed to stop TNFi treatment because of an intractable eruption. Female patients, patients with inflammatory alopecia and patients who were treated with methotrexate or phototherapy were more prone to stop TNFis.
Conclusions
TNFi-induced psoriasiform eruptions are common in paediatric patients with IBD. The eruption may appear months or even years after treatment initiation. Almost one-third of the described patients had to replace their treatment because of a recalcitrant cutaneous eruption. This indicates that a multidisciplinary approach is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
- Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Centre, Petach-Tikva, Israel.
- Division of Dermatology, Rabin Medical Center, Petah Tikva, Israel.
ORCID-Profile: Dror S Shouval
Zitieren
APA
Hilewitz, D., Yacobovitz, S., Reiss-Huss, S., Matar, M., Weintraub, Y., Shouval, D. S., Pavlovsky, L., & Friedland, R. (2025). Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae432
Vancouver
Hilewitz D, Yacobovitz S, Reiss-Huss S, Matar M, Weintraub Y, Shouval DS, et al. Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llae432
BibTeX
@article{Hilewitz2025,
author = {Hilewitz, Daniel and Yacobovitz, Sharon and Reiss-Huss, Shiran and Matar, Manar and Weintraub, Yael and Shouval, Dror S and Pavlovsky, Lev and Friedland, Rivka},
title = {Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-α inhibitors},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llae432}
}
EUVIMED